Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus
Mahendran Mahadevan(University of Arkansas Medical Center), Paul L. Hermonat(University of Arkansas for Medical Sciences), Hong You(Harbin Institute of Technology), Rongcheng Luo(Hebei Medical University), Jawahar L. Mehta(University of Arkansas for Medical Sciences), Changxuan You(Southern Medical University), Yong Liu(University of Arkansas for Medical Sciences)
Cited by 26
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment
|Hepatology|2016|156
TRPM7 regulates the migration of human nasopharyngeal carcinoma cell by mediating Ca2+ influx
|Cell Calcium|2010|135
CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients
|Biomedicine & Pharmacotherapy|2015|126